Clinical trials: Moderate-to-severe Psoriasis
Chronic Plaque Psoriasis
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis
This study will assess the use of risankizumab in adult patients with moderate to severe chronic plaque psoriasis and compare risankizumab to other commonly used biologics.
- Trial name
- VALUE (NCT03982394)
- Where
- 302 sites in Argentina, Australia and 19 more
- Volunteers
- 2,759 people
- Sponsor
- AbbVie
Psoriasis
Long-Term Effects of Infliximab in the Treatment of Moderate to Severe Psoriasis [Extension of Study P04271, NCT00251641] (P04563)
This is a long-term, randomized, multi-center, open-label study of infliximab treatment in adults with moderate to severe plaque-type psoriasis.
- Trial name
- NCT00358670
- Testing
- infliximab
- Volunteers
- 441 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Plaque Psoriasis
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis
This is a Phase 2a, multicenter, randomized, subject-blind, investigator-blind, study to investigate the pharmacokinetics (PK), pharmacodynamics (PD), and safety of bimekizumab in adult subjects with moderate to severe chronic…
- Trial name
- NCT03025542
- Testing
- Bimekizumab
- Where
- 8 sites in United States, Australia and 2 more
- Volunteers
- 49 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
A Study to Evaluate Comparative Efficacy and Safety of Guselkumab in High-dose and Extended-interval Versus Standard-dose in Chinese Participants of Moderate-to-severe Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety, tolerability and drug survival of guselkumab in high-dose and extended-interval versus standard-dose in Chinese participants with moderate to severe plaque psoriasis.
- Trial name
- NCT07532486
- Testing
- Guselkumab
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Psoriasis
DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the potential of DFD06 cream to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to clobetasol propionate cream, 0.05% cream when applied twice daily for 15 days.
- Trial name
- HPA axis (NCT02131324)
- Testing
- DFD06 Cream, Clobetasol Propionate Cream 0.05%
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- Promius Pharma, LLC
Moderate to Severe Plaque Psoriasis
Effectiveness of Adalimumab (HUMIRA®) in the Treatment of Scalp and Nail Affection in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
There is clearly a need for further data on the efficacy of biologic agents in the treatment of nail and scalp psoriasis, especially in the routine clinical setting.
- Trial name
- NCT01202565
- Where
- 73 sites in Czechia, Estonia and 6 more
- Volunteers
- 506 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis
Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies
This study will evaluate the safety and efficacy of brodalumab in the treatment of moderate-to-severe psoriasis in patients who have previously failed treatment with interleukin (IL)-17A therapies.
- Trial name
- NCT03403036
- Testing
- Brodalumab
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Psoriasis
A Study in Participants With Moderate to Severe Psoriasis
The primary purpose for this study is to help answer the following research questions The safety of ixekizumab (LY2439821) and any side effects that might be associated with it.
- Trial name
- NCT01107457
- Testing
- Ixekizumab
- Where
- 34 sites in United States, Denmark
- Volunteers
- 142 people
- Sponsor
- Eli Lilly and Company
Moderate to Severe Chronic Plaque Psoriasis
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a randomized, double-blind, active-controlled, parallel-group, multicenter study designed to compare the efficacy, safety, immunogenicity, and PK(Pharmacokinetic) of Bmab 1200 with Stelara in adult patients with moderate…
- Trial name
- STELLAR-2 (NCT05335356)
- Testing
- Stelara, Bmab1200
- Where
- United States
- Volunteers
- 384 people
- Sponsor
- Biocon Biologics UK Ltd
Psoriasis
Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.
This withdrawn study was to assess the safety and efficacy of secukinumab compared to etanercept and placebo in patients who have moderate to severe, chronic, plaque-type psoriasis.
- Trial name
- NCT01900782
- Testing
- Intervention A, Intervention B
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.
- Trial name
- NCT01208090
- Testing
- ACT-128800
- Where
- 67 sites in Austria, Belgium and 15 more
- Volunteers
- 326 people
- Sponsor
- Actelion
Psoriasis
A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis
This is a randomized, double-blind, placebo-controlled, multi-center Phase II clinical study to evaluate the efficacy and safety of AK111 for the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT05096364
- Where
- 13 sites in China
- Volunteers
- 251 people
- Sponsor
- Akeso
Moderate to Severe Psoriasis
Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy
Adalimumab has recently been authorized for active psoriasis in Peru and local experience is very low. The aim of this study is to obtain Peruvian data of clinical effectiveness and impact on health-related quality of life with…
- Trial name
- NCT01156532
- Where
- 3 sites in Peru
- Volunteers
- 30 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Psoriasis (PsO)
A Phase 2 Study of HB0017 in Psoriasis Patients
This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque…
- Trial name
- HB0017 (NCT06592274)
- Testing
- HB0017
- Where
- 18 sites in China
- Volunteers
- 206 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Psoriasis Vulgaris
Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis
This Phase II clinical study is to test safety and efficacy of BT061 against psoriasis given as repeated doses.
- Trial name
- NCT01072383
- Testing
- BT061
- Where
- 13 sites in Czechia, Hungary
- Volunteers
- 49 people
- Sponsor
- Biotest
Psoriasis
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
- Trial name
- POETYK-PSO-2 (NCT03611751)
- Testing
- BMS-986165, Apremilast
- Where
- 205 sites in United States, Australia and 14 more
- Volunteers
- 1,020 people
- Sponsor
- Bristol-Myers Squibb
Moderate to Severe Chronic Plaque Psoriasis
To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis
This is a Phase 3 Study to Compare Pharmacokinetics, Efficacy and Safety of CT-P17 with Humira in Patients with Moderate to Severe Chronic Plaque Psoriasis
- Trial name
- NCT05495568
- Testing
- CT-P17, EU-approved Humira
- Where
- Estonia
- Volunteers
- 367 people
- Sponsor
- Celltrion
Chronic Plaque Psoriasis
Raptiva in Palm and Sole Psoriasis
The primary purpose of the study is to evaluate the safety and efficacy of Raptiva® compared to placebo in controlling moderate to severe chronic plaque psoriasis involving palms and/or soles scoring Palmo-plantar Pustular…
- Trial name
- NCT00972543
- Testing
- Efalizumab (Raptiva)
- Volunteers
- 6 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Psoriasis, Plaque Psoriasis
Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients
This is a randomized, double-blind, placebo-controlled, multicenter clinical trial conducted in China. The study aims to evaluate the efficacy and safety of metformin combined with secukinumab in the treatment of…
- Conditions
- Psoriasis, Plaque Psoriasis, Moderate-to-severe Plaque Psoriasis, Overweight , Obesity
- Trial name
- NCT07485764
- Testing
- Secukinumab 300mg s.c., Metformin
- Where
- China
- Volunteers
- 186 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)
The purpose of the study is to evaluate the ability of subjects with moderate to severe chronic plaque psoriasis (PSO) to safely and effectively self-inject bimekizumab at study start and 8 weeks after training in self-injection…
- Trial name
- NCT03766685
- Testing
- Bimekizumab
- Where
- 39 sites in United States, Canada
- Volunteers
- 172 people
- Sponsor
- UCB Biopharma SRL